Ovarian cancer stem cells and methods of isolation and uses thereof
AssigneeThe General Hospital Corporation
InventorsPatricia K. Donahoe, David T. MacLaughlin, Jose Teixeira
Life of this patent
Estimating the term…
Abstract
The present invention generally relates to methods, assays, compositions and kits related to a subpopulation of ovarian cancer stem cells which are selected or enriched by chemotherapeutic agents and inhibited by MIS (Mullerian Inhibiting Substance) and MIS mimetics. In particular, the present invention relates to a population of CD44+/CD24+/EpCam+/ECad− subpopulation of ovarian cancer stem cells. The present invention also provides methods to screen a subject with ovarian cancer to identify if they have an ovarian cancer comprising CD44+/CD24+/EpCam+/ECad− ovarian cancer stem cells, and methods to identify and enrich or isolate for such ovarian cancer cell populations.
Claims6
A method to detect the presence of ovarian cancer stem cells in a population of ovarian cancer cells, the method comprising;
- (a) contacting the population of ovarian cancer cells with an anti-CD24 antibody, an anti-CD44 antibody, an anti-EpCam antibody and an anti-E-Cadherin antibody;
- and
- (b) detecting whether an ovarian cancer cell is positive for the expression of CD24, CD44, EpCam and negative for the expression of E-Cadherin by detecting positive binding between;
- CD24 and the anti-CD24 antibody, CD44 and the anti-CD44 antibody, EpCam and the anti-EpCam antibody and detecting negative binding between E-Cadherin and the anti-E-Cadherin antibody,
- wherein the detected ovarian cancer stem cells that are positive for the expression of CD24, CD44, EpCam and negative for the expression of E-Cadherin are responsive to inhibition of proliferation by MIS.
A method of diagnosing and treating a subject with ovarian cancer comprising ovarian cancer stem cells, the method comprising:
- (a) contacting a population of ovarian cancer cells obtained from the subject with an anti-CD24 antibody, an anti-CD44 antibody, an anti-EpCam antibody and an anti-E-Cadherin antibody;
- and
- (b) detecting whether an ovarian cancer stem cell is present in the population of ovarian cancer cells, by detecting whether an ovarian cancer cell is positive for the expression of CD24, CD44, EpCam and negative for the expression of E-Cadherin by detecting positive binding between;
- CD24 and the anti-CD24 antibody, CD44 and the anti-CD44 antibody, EpCam and the anti-EpCam antibody and detecting negative binding between E-Cadherin and the anti-E-Cadherin antibody;
- (c) diagnosing the subject with ovarian cancer comprising ovarian cancer stem cells when an ovarian cancer cell positive for the expression of CD24, CD44, EpCam and negative for the expression of E-Cadherin is detected;
- and
- (d) administering a pharmaceutically effective amount of MIS or a MIS mimetic to the diagnosed subject.
Dependencies are inferred from the claim text.